Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $812.00 Price Target at Sanford C. Bernstein

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective raised by Sanford C. Bernstein from $756.00 to $812.00 in a report issued on Monday, Benzinga reports. The firm currently has a “market perform” rating on the biopharmaceutical company’s stock. Sanford C. Bernstein‘s target price points to a potential downside of 15.46% from the company’s previous close.

REGN has been the topic of a number of other reports. UBS Group raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $660.00 to $978.00 in a research report on Thursday, October 15th. Canaccord Genuity Group upped their target price on shares of Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the company a “buy” rating in a research note on Wednesday, October 28th. Leerink Partners raised their price target on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a report on Monday, August 17th. The Goldman Sachs Group lifted their price target on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Bank of America lifted their price target on shares of Regeneron Pharmaceuticals from $908.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $891.90.

Regeneron Pharmaceuticals Stock Up 3.5%

Shares of NASDAQ:REGN traded up $32.55 during mid-day trading on Monday, hitting $960.44. 975,692 shares of the company traded hands, compared to its average volume of 823,074. The firm has a market cap of $98.89 billion, a P/E ratio of 21.21, a PEG ratio of 1.57 and a beta of 0.10. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.66 and a current ratio of 4.06. Regeneron Pharmaceuticals has a 52-week low of $591.52 and a 52-week high of $974.00. The firm’s 50 day simple moving average is $793.30 and its 200 day simple moving average is $738.05.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping the consensus estimate of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. Regeneron Pharmaceuticals’s revenue for the quarter was up 36.3% on a year-over-year basis. During the same period in the previous year, the company posted $11.83 EPS. On average, equities analysts anticipate that Regeneron Pharmaceuticals will post 49.10 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the completion of the transaction, the director owned 603 shares of the company’s stock, valued at $512,550. This trade represents a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,093 shares of company stock worth $6,506,845 over the last quarter. Company insiders own 6.97% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. LCM Capital Management Inc increased its holdings in shares of Regeneron Pharmaceuticals by 2.2% in the 3rd quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company’s stock valued at $467,000 after acquiring an additional 13 shares during the last quarter. Arjuna Capital lifted its stake in Regeneron Pharmaceuticals by 3.2% during the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock worth $353,000 after purchasing an additional 14 shares during the last quarter. Oakworth Capital Inc. lifted its stake in Regeneron Pharmaceuticals by 25.0% during the third quarter. Oakworth Capital Inc. now owns 70 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 14 shares during the last quarter. Geneos Wealth Management Inc. lifted its stake in Regeneron Pharmaceuticals by 1.8% during the first quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock worth $645,000 after purchasing an additional 15 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. boosted its holdings in Regeneron Pharmaceuticals by 30.2% in the first quarter. Whittier Trust Co. of Nevada Inc. now owns 69 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 16 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts broadly raised their forecasts following the upbeat quarter. Guggenheim increased its target to $1,100 with a “buy” rating, JPMorgan raised its target to $1,050 and assigned an “overweight” rating, and Bank of America lifted its target to $1,030 while maintaining a “buy” rating. Other firms also raised targets, with some forecasts reportedly reaching as high as $1,175. Analysts Raise Their Forecasts on Regeneron Pharmaceuticals After Upbeat Q3 Results
• Positive Sentiment: The combination of 70% EPS growth, 36% revenue growth, continued Dupixent momentum, encouraging Libtayo data and an expanded BARDA Ebola-treatment supply agreement points to improving commercial execution and pipeline value. Regeneron Earnings Call Highlights Explosive Growth, Deep Pipeline
• Positive Sentiment: Recent earnings-driven buying pushed REGN to a new one-year high, signaling strong market momentum and improved sentiment around the company’s growth outlook. Regeneron Hits 52-Week High After Standout Q3
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable December 3 to shareholders of record November 20. The annualized yield is approximately 0.4%, providing modest shareholder income.
• Negative Sentiment: Several updated targets remain below the current trading level: RBC set $913 with a “sector perform” rating, Wells Fargo set $925 with “equal weight,” and Baird set $875 with “neutral.” These calls suggest some analysts view the recent rally as having limited near-term upside.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.